In this large trial of patients with VTE who had already completed 6-12 months of anticoagulation, they were randomized to 12 additional months of apixaban (5 or 10mg bid) versus placebo. Recurrent VTE occurred in 9% of the placebo group, versus 2% of each of the treatment groups. Bleeding occurred in <0.5% of each group. Long term apixaban is effective and safe for reducing recurrent VTE (abstract).
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]